Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312656 | 0.78 | SIRT5 (0.46) | NPSR1LMNAL3MBTL1CA1CA2 | |
| SCHEMBL6321645 | 0.78 | TSHR (0.43) | NPSR1LMNAL3MBTL1TSHRMEN1 | |
| SCHEMBL6320179 | 0.78 | NPC1 (0.43) | NPSR1LMNAL3MBTL1KMT2ACA1 | |
| SCHEMBL6320988 | 0.78 | KMT2A (0.48) | NPSR1L3MBTL1TSHRKMT2A | |
| SCHEMBL6312283 | 0.77 | CA1 (0.41) | NPSR1MMEACELMNAL3MBTL1 | |
| SCHEMBL6319508 | 0.75 | NPC1 (0.43) | NPSR1LMNAL3MBTL1CA1CA2 | |
| SCHEMBL4523453 | 0.71 | CA1 (0.57) | LMNAL3MBTL1ITGB3CA1CA2 | |
| SCHEMBL6313462 | 0.70 | CYP2C19 (0.45) | L3MBTL1 | |
| SCHEMBL4324944 | 0.70 | NPSR1 (0.46) | NPSR1TSHRMEN1KMT2AHIF1A | |
| SCHEMBL6312483 | 0.70 | NPSR1 (0.48) | NPSR1LMNAL3MBTL1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | NPSR1 198/4885MME 1598/4885ACE 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.